BiotechTube

CERE-110: Adeno-Associated Virus injection Surgery

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alzheimer's Disease

Conditions

Alzheimer's Disease

Trial Timeline

Nov 1, 2008 → Aug 13, 2015

NCT ID
NCT00876863

About CERE-110: Adeno-Associated Virus injection Surgery

CERE-110: Adeno-Associated Virus injection Surgery is a phase 2 stage product being developed by Sangamo Therapeutics for Alzheimer's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00876863. Target conditions include Alzheimer's Disease.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00876863Phase 2Completed

Competing Products

20 competing products in Alzheimer's Disease

See all competitors
ProductCompanyStageHype Score
LY450139 + PlaceboEli LillyPhase 3
77
Solanezumab + PlaceboEli LillyPhase 3
77
LY450139 dihydrate + placeboEli LillyPhase 2
52
GSK4527226AlectorPhase 2
44
GSK4527226AlectorPhase 2
44
AL002AlectorPhase 2
44
Solanezumab + PlaceboEli LillyPhase 3
77
simufilamCassava SciencesPhase 2
44
Remternetug + PlaceboEli LillyPhase 3
77
solanezumabEli LillyPhase 2
52
LY2886721 + PlaceboEli LillyPhase 1
33
Gantenerumab + Gantenerumab + Gantenerumab + PlaceboChugai PharmaceuticalPhase 1
33
Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved
85
FK962Astellas PharmaPhase 2
52
ASP0777 + PlaceboAstellas PharmaPhase 1
33
Elenbecestat + PlaceboEisaiPhase 3
77
DonepezilEisaiApproved
85
Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg)EisaiPhase 3
77
Donepezil hydrochlorideEisaiPhase 3
77
Donepezil HydrochlorideEisaiPre-clinical
23

Other Products from Sangamo Therapeutics

SB-509Phase 2
44
SB-509Phase 2
44
SB-509Phase 2
44
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])Phase 2
44
SB-509Phase 2
44